News

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...
Senator Maggie Hassan launches an investigation into GlaxoSmithKline's withdrawal of a popular asthma inhaler, linking it to ...
GlaxoSmithKline said it would buy cancer-focused drug company Tesaro for about $4.16 billion, positioning the health-care giant in a promising, but fiercely competitive, area of medicine.
The presented data provides a snapshot of the financial health and recent market performance of key stocks within the NIFTY MIDCAP 150 index.
GlaxoSmithKline Chief Executive Andrew Witty is pictured after he was presented with his Knighthood. (Image credit: AFP/Getty Images via @daylife) This morning, GlaxoSmithKline announced a $3 ...
GlaxoSmithKline, which is based in London, was formed on Jan. 1, 2001 by the $76 billion merger of Glaxo Wellcome, the maker of Wellbutrin (depression) and Imitrex (migraines), and SmithKline ...
Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs for its inhalers at $35 a month, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow through ...
GlaxoSmithKline LLC will pay $3 billion and plead guilty to promoting two popular drugs for unapproved uses and to failing to disclose important safety information on a third in the largest heal ...
GlaxoSmithKline’s headquarters are in Brentford, U.K. The pharmaceutical firm will relocate its commercial division to Weybridge by 2022. Still, its R&D and Vaccines Business will continue in ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster ...
GlaxoSmithKline Pharmaceuticals, with its shares currently priced at Rs 3,292.30, remains a key stock to watch, particularly for those invested in or tracking the NIFTY MIDCAP 150 index.
U.S. Senator Maggie Hassan has initiated an investigation into GlaxoSmithKline's decision to discontinue the Flovent HFA ...